Boulder: Fifth Subject Enrolled; MDMA Encapsulated for New Dose Group
On January 22, the fifth subject was enrolled in our ongoing study of MDMA-assisted psychotherapy for PTSD taking place in Boulder, Colorado. (Note: We are now subtracting dropouts from the total number of subjects treated to more accurately reflect study progress.) The fourth subject received their second experimental treatment on January 17. The second subject, who dropped out after one treatment session due to scheduling difficulties despite feeling improved, has agreed to return for her one-year follow-up. On January 21, the MDMA was encapsulated for the new 100 mg dose group and for Stage 2 of the study protocol. Led by Principal Investigator Marcela Ot’alora, this study will treat 17 subjects with chronic, treatment-resistant PTSD resulting from sexual assault, military service, violent crime, or other causes. As of January 31, we have received 214 inquiries for participation in this study.